Abstract
Pulmonary arterial hypertension (PAH) is a rare, incurable disease characterized by adverse remodeling of the pulmonary vasculature, leading to increased pulmonary arterial pressures and right ventricular failure. Contemporary pharmacotherapy targets 3 distinct molecular pathways that are abnormal in PAH: deficient production of nitric oxide and prostacyclin, and over production of endothelin. Risk assessment is critical in guiding therapeutic decision making and in disease surveillance following treatment initiation. Patients with more advanced disease are best treated with continuous infusion therapy, while those less symptomatic patients may respond to oral or inhaled therapies. Combination therapy is being increasingly utilized in patients who fail to achieve treatment goals.
Keywords: Pulmonary hypertension, pulmonary arterial hypertension, right ventricle failure, prostacyclins, endothelin receptor antagonist.
Current Pharmaceutical Design
Title:Pharmacologic Treatment of Pulmonary Arterial Hypertension
Volume: 19 Issue: 22
Author(s): Gautam V. Ramani and Sartraj Gill
Affiliation:
Keywords: Pulmonary hypertension, pulmonary arterial hypertension, right ventricle failure, prostacyclins, endothelin receptor antagonist.
Abstract: Pulmonary arterial hypertension (PAH) is a rare, incurable disease characterized by adverse remodeling of the pulmonary vasculature, leading to increased pulmonary arterial pressures and right ventricular failure. Contemporary pharmacotherapy targets 3 distinct molecular pathways that are abnormal in PAH: deficient production of nitric oxide and prostacyclin, and over production of endothelin. Risk assessment is critical in guiding therapeutic decision making and in disease surveillance following treatment initiation. Patients with more advanced disease are best treated with continuous infusion therapy, while those less symptomatic patients may respond to oral or inhaled therapies. Combination therapy is being increasingly utilized in patients who fail to achieve treatment goals.
Export Options
About this article
Cite this article as:
V. Ramani Gautam and Gill Sartraj, Pharmacologic Treatment of Pulmonary Arterial Hypertension, Current Pharmaceutical Design 2013; 19 (22) . https://dx.doi.org/10.2174/1381612811319220004
DOI https://dx.doi.org/10.2174/1381612811319220004 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Statins Therapy may Change a Course of Lung Fibrosis and Pulmonary Hypertension: A New Indication for Therapy or Just “Statinomania”?
Current Respiratory Medicine Reviews Role of NUCB2/nesfatin-1 as a Possible Biomarker
Current Pharmaceutical Design Interactive Effect of Cigarette Smoking and Gene Variants for Predisposing to Cardiovascular Disease
Current Pharmaceutical Design Modifiable Risk Factors Associated with Alzheimer’s Disease with Special Reference to Sleep Disturbance
CNS & Neurological Disorders - Drug Targets Risk Assessment of Obstructive Sleep Apnea and its Association with Fatigue and Sleepiness Among Hospital Inpatients
Current Respiratory Medicine Reviews Xenobiotic Metabolising Enzymes: Impact on Pathologic Conditions, Drug Interactions and Drug Design
Current Topics in Medicinal Chemistry Meet the Editorial Board
Current Vascular Pharmacology Detection of Myocardial Ischemia in Patients with Blunted Hemodynamic Response to Adenosine Stress
Current Medical Imaging Patent Selections
Recent Patents on Drug Delivery & Formulation Effects of Gene and Plasma Tau on Cognitive Impairment in Rural Chinese Population
Current Alzheimer Research Potassium Channel Blockers and Openers as CNS Neurologic Therapeutic Agents
Recent Patents on CNS Drug Discovery (Discontinued) Unraveling Progesterone-Induced Molecular Mechanisms in Physiological and Pathological Conditions
Current Clinical Pharmacology HIV-1 Infection in Subjects Older than 70: A Multicenter Cross-Sectional Assessment in Catalonia, Spain
Current HIV Research Carotid Ultrasound in One, Two and Three Dimensions
Vascular Disease Prevention (Discontinued) Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse
Current Respiratory Medicine Reviews Design and Ocular Tolerance of Flurbiprofen Loaded Nanosuspension
Pharmaceutical Nanotechnology Peroxisome Proliferator-Activated Receptor-γ: Master Regulator of Adipogenesis and Obesity
Current Stem Cell Research & Therapy Engagement of Renin-Angiotensin System in Prostate Cancer
Current Cancer Drug Targets Clinical Application of PET Myocardial Perfusion Imaging
Current Medical Imaging Pulmonary Hemorrhage in Patients with Systemic Lupus Erythematosus
Current Respiratory Medicine Reviews